Generex's New Plan: Spinout, Reverse Stock Split And Continued Focus On Oral Insulin
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm believes buccal delivery of oral insulin will succeed where inhaled insulins have failed or stalled in development.